Suraksha Diagnostic Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 28 May 2026 | Healthcare Services | Market Cap: ₹1.6K Cr
FY26 revenue grew 23.1% YoY to INR3,104.1 million, with a three-year CAGR of 17.78% indicating strong structural growth. Revenue growth guidance for FY27 and beyond is around 15%, despite a 23% growth in FY26, with the company preferring cautious estimates and aiming to potentially over-deliver.
From Suraksha Diagnostic Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹326
Market Cap
₹1.6K Cr
P/E Ratio
44.4
How does Suraksha Diagnostic Ltd rank in Healthcare Services?
Compare Suraksha Diagnostic Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.
Suraksha Diagnostic Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹81 Cr, net profit ₹6 Cr.
Full financials →📊 Revenue & Sales Performance
- →FY26 revenue grew 23.1% YoY to INR3,104.1 million, with a three-year CAGR of 17.78% indicating strong structural growth.
- →FY27 revenue growth guidance is around 15%, with management open to over-delivering but committing to a conservative 15%.
- →Growth drivers include:
- → - Expansion: Adding multiple new hubs and spoke centers targeting West Bengal, Bihar, Jharkhand, and Tripura, increasing network size from 68 centers in FY26 to 82+ in FY27.
- → - New centers expected to contribute majority of growth; mature centers to contribute ~9% growth.
- → - Focus on ramping up throughput and capacity utilization in recently launched centers.
- → - Increasing share of specialized diagnostics and premium test mix, including genomics and advanced radiology.
- → - Geographic expansion beyond West Bengal, including Assam, Guwahati, and Tripura.
- →Long-term, EBITDA margins projected to stabilize around 35%, reflecting operational leverage from scale.
📈 Profitability & Margins
- →Revenue growth guidance for FY27 and beyond is around 15%, despite a 23% growth in FY26, with the company preferring cautious estimates and aiming to potentially over-deliver.
- →EBITDA margin expected to stabilize at approximately 33% in FY27 due to expansion and pre-operative expenses, improving to around 35% in the mid-term and 38-39% over the long term as new centers mature.
- →Mature centers deliver EBITDA margins of 36-37%, and new centers currently operate at negative EBITDA but are expected to breakeven within 5-12 months at the center level and 1-2 quarters later at the HO expense level.
- →PAT growth was modest at 1.4% in FY26, impacted by expansion costs and depreciation; improvement likely as operating leverage improves.
- →Earnings per share (EPS) and profits expected to strengthen as new centers mature, revenues scale, and cost efficiencies improve.
🏗️ Capital Expenditure Plans
- →Planned capex for FY27 is around INR 70 crores.
- →Capex includes opening five new hub centers and eight asset-light spoke centers.
- →Expansion targets West Bengal, Bihar, Jharkhand, and Tripura.
- →Two centers planned for last year had delayed openings; capex for those is nearly incurred.
- →The company is focused on building specialized hubs and scaling diagnostics like genomics and advanced imaging.
- →Long-term strategy includes sweating central reference infrastructure and improving throughput in new centers.
- →Capex supports multi-state expansion, moving Suraksha from state leader to regional player.
💰 Fundraising & Capital Structure
- →There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript.
- →The company has talked about capitalization of around INR70 crores planned for network expansion in FY27, but no mention of the source of this capex funding.
- →Financials reflect expenses relating to expansion and new centers, impacting margins, but no reference to raising capital externally.
- →Management focuses on organic growth, operational improvements, and internal accruals from the business.
- →No question or answer during the call discussed plans for issuing new debt or equity instruments at this time.
📋 Order Book & Pipeline
Key Metrics
Continue your research
What Suraksha Diagno.'s management said in earlier quarters
Others in Healthcare Services this season
- Apollo Hospitals Enterprise Ltd (Q4 FY26)
30% growth currently driven by top 5 markets; expansion planned into new markets. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY26 earnings…
- Health X Platform (Q4 FY26)
Northeast operations growing 50%+ year-on-year and Northern India 25–30%, with plans for 5–7% market share in 2-3 years (Page 10). Key concall takeaways from…
- Park Medi World (Q4 FY26)
Total planned capex for the next two years is around INR 500 crores. Key concall takeaways from Park Medi World's Q4 FY26 earnings call — and how it ranks…
- Vimta Labs (Q4 FY26)
. Key concall takeaways from Vimta Labs Ltd's Q4 FY26 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were Suraksha Diagnostic Ltd Q4 FY26 results?
FY26 revenue grew 23.1% YoY to INR3,104.1 million, with a three-year CAGR of 17.78% indicating strong structural growth. Revenue growth guidance for FY27 and beyond is around 15%, despite a 23% growth in FY26, with the company preferring cautious estimates and aiming to potentially over-deliver.
What is Suraksha Diagnostic Ltd share price analysis?
Suraksha Diagnostic Ltd currently shows a neutral. The stock trades at a P/E of 44.4 with a market cap of ₹1,588 Cr. Investors should review the full earnings analysis for detailed insights.
Is Suraksha Diagnostic Ltd planning capital expenditure?
Planned capex for FY27 is around INR 70 crores.
Keep Suraksha Diagnostic Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.